Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) Interest Expenses (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Interest Expenses for 7 consecutive years, with $92000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Interest Expenses rose 55.93% to $92000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $370000.0, a 48.59% increase, with the full-year FY2025 number at $370000.0, up 48.59% from a year prior.
  • Interest Expenses was $92000.0 for Q4 2025 at Kymera Therapeutics, down from $98000.0 in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $108000.0 in Q2 2025 to a low of $24000.0 in Q1 2021.
  • A 5-year average of $58300.0 and a median of $57000.0 in 2022 define the central range for Interest Expenses.
  • Peak YoY movement for Interest Expenses: surged 150.0% in 2021, then plummeted 48.57% in 2022.
  • Kymera Therapeutics' Interest Expenses stood at $51000.0 in 2021, then rose by 15.69% to $59000.0 in 2022, then decreased by 11.86% to $52000.0 in 2023, then increased by 13.46% to $59000.0 in 2024, then skyrocketed by 55.93% to $92000.0 in 2025.
  • Per Business Quant, the three most recent readings for KYMR's Interest Expenses are $92000.0 (Q4 2025), $98000.0 (Q3 2025), and $108000.0 (Q2 2025).